Study of FHIT and WWOX expression in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary gland

Oral Oncology

Volumn 46, Issue 3, 2010, Pages 195-199

  Dincer, Nazmiye ^a   Tezel, Gaye Güler ^a   Sungur, Arzu ^a   Himmetoglu, Cigdem ^a   Huebner, Kay ^b   Güler, Gülnur ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Adenoid cystic carcinoma; Basal like phenotype; FHIT; Mucoepidermoid carcinoma; Salivary gland cancer; WWOX

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN;

ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CHILD; CHROMATIN STRUCTURE; CHROMOSOME FRAGILE SITE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PATHOGENESIS; PRIORITY JOURNAL; SALIVARY GLAND CARCINOMA; SCHOOL CHILD; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; WWOX GENE;

ACID ANHYDRIDE HYDROLASES; ADOLESCENT; ADULT; AGED; CARCINOMA, ADENOID CYSTIC; CARCINOMA, MUCOEPIDERMOID; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHROMOSOME FRAGILE SITES; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OXIDOREDUCTASES; PROGNOSIS; SALIVARY GLAND NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 76749128434     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2009.12.003     Document Type: Article

References (46)

1. Lopes M.A., Kowalski L.P., da Cunha Santos G., and Paes de Almeida O. A clinicopathologic study of 196 intraoral minor salivary gland tumours. J Oral Pathol Med 28 6 (1999) 264-267
2. Spiro R.H., Huvos A.G., and Strong E.W. Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg 128 4 (1974) 512-520
3. Monoo K., Sageshima M., Ito E., Nishihira S., and Ishikawa K. Histopathological grading and clinical features of patients with mucoepidermoid carcinoma of the salivary glands. Nippon Jibiinkoka Gakkai Kaiho 106 3 (2003) 192-198
4. Solomon E., Borrow J., and Goddard A.D. Chromosome aberrations and cancer. Science 254 5035 (1991) 1153-1160
5. Huebner K., Garrison P.N., Barnes L.D., and Croce C.M. The role of the FHIT/FRA3B locus in cancer. Annu Rev Genet 32 (1998) 7-31
6. Iliopoulos D., Guler G., Han S.Y., Druck T., Ottey M., McCorkell K.A., et al. Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett 232 1 (2006) 27-36
7. Paige A.J., Taylor K.J., Taylor C., Hillier S.G., Farrington S., Scott D., et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA 98 20 (2001) 11417-11422
8. Guler G., Huebner K., Himmetoglu C., Jimenez R.E., Costinean S., Volinia S., et al. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. Cancer 115 4 (2009) 899-908
9. Guler G., Uner A., Guler N., Han S.Y., Iliopoulos D., McCue P., et al. Concordant loss of fragile gene expression early in breast cancer development. Pathol Int 55 8 (2005) 471-478
10. Sozzi G., Tornielli S., Tagliabue E., Sard L., Pezzella F., Pastorino U., et al. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 57 23 (1997) 5207-5212
11. Mori M., Mimori K., Shiraishi T., Alder H., Inoue H., Tanaka Y., et al. Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res 60 5 (2000) 1177-1182
12. Connolly D.C., Greenspan D.L., Wu R., Ren X., Dunn R.L., Shah K.V., et al. Loss of Fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res 6 9 (2000) 3505-3510
13. Huebner K., Hadaczek P., Siprashvili Z., Druck T., and Croce C.M. The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Biochim Biophys Acta 1332 3 (1997) M65-M70
14. Huebner K., Druck T., Siprashvili Z., Croce C.M., Kovatich A., and McCue P.A. The role of deletions at the FRA3B/FHIT locus in carcinogenesis. Recent Results Cancer Res 154 (1998) 200-215
15. Barnes L.D., Garrison P.N., Siprashvili Z., Guranowski A., Robinson A.K., Ingram S.W., et al. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′,5′″-P1, P3-triphosphate hydrolase. Biochemistry 35 36 (1996) 11529-11535
16. Baffa R., Veronese M.L., Santoro R., Mandes B., Palazzo J.P., Rugge M., et al. Loss of FHIT expression in gastric carcinoma. Cancer Res 58 20 (1998) 4708-4714
17. Noguchi T., Muller W., Wirtz H.C., Willers R., and Gabbert H.E. FHIT gene in gastric cancer: association with tumour progression and prognosis. J Pathol 188 4 (1999) 378-381
18. Hadaczek P., Debniak T., Kurzawski G., Jakubowska A., Huzarski T., Huebner K., et al. Fhit protein expression in hereditary and sporadic colorectal cancers. Pol J Pathol 52 3 (2001) 125-132
19. Lee S.H. Aberrant FHIT transcripts in human colorectal cancers. Res Commun Mol Pathol Pharmacol 117-118 (2005) 153-165
20. Zanesi N., Mancini R., Sevignani C., Vecchione A., Kaou M., Valtieri M., et al. Lung cancer susceptibility in Fhit-deficient mice is increased by Vhl haploinsufficiency. Cancer Res 65 15 (2005) 6576-6582
21. Zanesi N., Fidanza V., Fong L.Y., Mancini R., Druck T., Valtieri M., et al. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA 98 18 (2001) 10250-10255
22. Dumon K.R., Ishii H., Fong L.Y., Zanesi N., Fidanza V., Mancini R., et al. FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci USA 98 6 (2001) 3346-3351
23. Campiglio M., Pekarsky Y., Menard S., Tagliabue E., Pilotti S., and Croce C.M. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 59 16 (1999) 3866-3869
24. Michael D., Beer D.G., Wilke C.W., Miller D.E., and Glover T.W. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas. Oncogene 15 14 (1997) 1653-1659
25. Birrer M.J., Hendricks D., Farley J., Sundborg M.J., Bonome T., Walts M.J., et al. Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res 59 20 (1999) 5270-5274
26. Yuge T., Nibu K., Kondo K., Shibahara J., Tayama N., and Sugasawa M. Loss of FHIT expression in squamous cell carcinoma and premalignant lesions of the larynx. Ann Otol Rhinol Laryngol 114 2 (2005) 127-131
27. Ozaki K., Enomoto T., Yoshino K., Fujita M., Buzard G.S., Kawano K., et al. Impaired FHIT expression characterizes serous ovarian carcinoma. Br J Cancer 85 2 (2001) 247-254
28. Man S., Ellis I.O., Sibbering M., Blamey R.W., and Brook J.D. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Cancer Res 56 23 (1996) 5484-5489
29. Ishii H., Vecchione A., Furukawa Y., Sutheesophon K., Han S.Y., Druck T., et al. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res 1 13 (2003) 940-947
30. Nunez M.I., Ludes-Meyers J., Abba M.C., Kil H., Abbey N.W., Page R.E., et al. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat 89 2 (2005) 99-105
31. Nakayama S., Semba S., Maeda N., Aqeilan R.I., Huebner K., and Yokozaki H. Role of the WWOX gene, encompassing fragile region FRA16D, in suppression of pancreatic carcinoma cells. Cancer Sci 99 7 (2008) 1370-1376
32. Kuroki T., Yendamuri S., Trapasso F., Matsuyama A., Aqeilan R.I., Alder H., et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 10 7 (2004) 2459-2465
33. Iliopoulos D., Guler G., Han S.Y., Johnston D., Druck T., McCorkell K.A., et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 24 9 (2005) 1625-1633
34. Ludes-Meyers J.H., Bednarek A.K., Popescu N.C., Bedford M., and Aldaz C.M. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res 100 1-4 (2003) 101-110
35. Nunez M.I., Ludes-Meyers J., and Aldaz C.M. WWOX protein expression in normal human tissues. J Mol Histol 37 3-4 (2006) 115-125
36. Lewandowska U., Zelazowski M., Seta K., Byczewska M., Pluciennik E., and Bednarek A.K. WWOX, the tumour suppressor gene affected in multiple cancers. J Physiol Pharmacol 60 Suppl. 1 (2009) 47-56
37. Chang N.S., Doherty J., Ensign A., Schultz L., Hsu L.J., and Hong Q. WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. J Biol Chem 280 52 (2005) 43100-43108
38. Qin H.R., Iliopoulos D., Nakamura T., Costinean S., Volinia S., Druck T., et al. Wwox suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling. Mol Cancer Res 5 9 (2007) 957-965
39. Qin H.R., Iliopoulos D., Semba S., Fabbri M., Druck T., Volinia S., et al. A role for the WWOX gene in prostate cancer. Cancer Res 66 13 (2006) 6477-6481
40. Bloomston M., Kneile J., Butterfield M., Dillhoff M., Muscarella P., Ellison E.C., et al. Coordinate loss of fragile gene expression in pancreatobiliary cancers: correlations among markers and clinical features. Ann Surg Oncol 16 8 (2009) 2331-2338
41. Guler G., Uner A., Guler N., Han S.Y., Iliopoulos D., Hauck W.W., et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 100 8 (2004) 1605-1614
42. Honeth G., Bendahl P.O., Ringner M., Saal L.H., Gruvberger-Saal S.K., Lövgren K., et al. The CD44+/CD24-phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10 3 (2008) R53
43. Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., Gilcrease M.Z., Krishnamurthy S., Lee J.S., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69 10 (2009) 4116-4124
44. Miyoshi Y., Murase K., and Oh K. Basal-like subtype and BRCA1 dysfunction in breast cancers. Int J Clin Oncol 13 5 (2008) 395-400
45. Ishii H., Wang Y., and Huebner K. A Fhit-ing role in the DNA damage checkpoint response. Cell Cycle 6 9 (2007) 1044-1048
46. Cantor J.P., Iliopoulos D., Rao A.S., Druck T., Semba S., Han S.Y., et al. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity. Int J Cancer 120 1 (2007) 24-31